Published in Gastric Cancer on July 04, 2014
Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer (2015) 1.07
Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer? Surg Today (2014) 0.91
Associations between serum CA724 and HER2 overexpression among stage II-III resectable gastric cancer patients: an observational study. Oncotarget (2016) 0.78
Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today (2017) 0.77
The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol (2017) 0.75
Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers. Gastroenterol Res Pract (2016) 0.75
Conversion therapy for stage IV gastric cancer-the present and future. Transl Gastroenterol Hepatol (2016) 0.75
Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma. ScientificWorldJournal (2016) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28
Japanese Classification of Gastric Carcinoma - 2nd English Edition - Gastric Cancer (1998) 16.63
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med (2008) 9.00
Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology (2008) 5.31
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol (2008) 4.63
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol (2005) 4.00
HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci (2006) 2.53
Fixation time does not affect expression of HER2/neu: a pilot study. Am J Clin Pathol (2010) 2.05
HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol (2010) 1.93
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep (2006) 1.91
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer (2009) 1.82
Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res (2012) 1.74
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol (2012) 1.65
HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer (2012) 1.54
Delay to formalin fixation effect on breast biomarkers. Mod Pathol (2009) 1.46
Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg (2009) 1.43
Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg (2014) 1.31
Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology (2011) 1.16
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer (2011) 1.08
Principles of surgical treatment for curable gastric cancer. J Clin Oncol (2003) 1.03
Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol (2004) 0.98
Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol (2012) 0.93
Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci (2012) 0.88
HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int J Oncol (2003) 0.87
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med (2007) 12.62
D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med (2008) 9.00
Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer (2000) 8.85
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol (2010) 6.60
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol (2011) 6.53
Randomised trials in surgery: problems and possible solutions. BMJ (2002) 5.53
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA (2010) 5.04
Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol (2011) 4.48
Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol (2004) 4.31
Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol (2010) 3.64
Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res (2009) 3.50
Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer (2006) 3.06
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet (2008) 2.89
Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol (2006) 2.73
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol (2008) 2.65
Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res (2007) 2.39
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. Ann Surg Oncol (2008) 2.32
Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer (2008) 2.32
Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A (2002) 2.27
Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol (2003) 2.27
Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases. Am J Surg Pathol (2008) 2.22
Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer (2011) 2.18
Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer (2012) 2.09
Endoscopic evaluation of the remnant stomach after gastrectomy: proposal for a new classification. Gastric Cancer (2002) 2.01
Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun (2003) 2.00
Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol (2008) 1.93
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem (2008) 1.92
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep (2006) 1.91
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci (2008) 1.87
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 1.85
c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol (2003) 1.84
Focus on gastric cancer. Cancer Cell (2004) 1.82
Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer (2010) 1.81
Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer (2009) 1.80
Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res (2012) 1.74
Histopathologic prognostic factors in resected colorectal lung metastases. Ann Thorac Surg (2005) 1.71
Efficacy of capillary pattern type IIIA/IIIB by magnifying narrow band imaging for estimating depth of invasion of early colorectal neoplasms. BMC Gastroenterol (2010) 1.68
Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood (2008) 1.66
Diagnosis and surgical outcomes for primary malignant melanoma of the esophagus: a single-center experience. Ann Thorac Surg (2013) 1.64
Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol (2004) 1.63
Treatment of early gastric cancer in the elderly patient: results of EMR and gastrectomy at a national referral center in Japan. Gastrointest Endosc (2005) 1.60
Peritoneal elastic laminal invasion of colorectal cancer: the diagnostic utility and clinicopathologic relationship. Am J Surg Pathol (2010) 1.60
Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer (2008) 1.59
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer (2011) 1.58
A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med (2002) 1.57
Improving outcomes after gastroesophageal cancer resection: can Japanese results be reproduced in Western centers? Arch Surg (2012) 1.55
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res (2004) 1.54
Pancreaticoduodenectomy for advanced gastric cancer. Gastric Cancer (2005) 1.53
Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest (2007) 1.53
Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. J Sex Med (2010) 1.53
Short- and long-term outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. Endoscopy (2013) 1.52
Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int (2007) 1.50
Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol (2002) 1.46
Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol (2002) 1.45
Primary gastric choriocarcinoma: two case reports and a pooled analysis of 53 cases. Gastric Cancer (2005) 1.44
Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. J Gastroenterol (2005) 1.44
Immunohistochemical analysis of cell cycle-regulating-protein (p21, p27, and Ki-67) expression in gastroesophageal reflux disease. J Gastroenterol (2002) 1.42
Retroperitoneal ancient schwannoma presenting as an adrenal incidentaloma: CT and MR findings. Magn Reson Imaging (2006) 1.42
Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci (2008) 1.42
Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies. J Urol (2007) 1.41
Localized pure ground-glass opacity on high-resolution CT: histologic characteristics. J Comput Assist Tomogr (2002) 1.41
STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol (2014) 1.41
Practical utility and objectivity: does evaluation of peritoneal elastic laminal invasion in colorectal cancer overcome these contrary problems? Am J Surg Pathol (2014) 1.40
Clinicopathological characteristics of follicular lymphoma with peripheral blood involvement. Leuk Lymphoma (2014) 1.39
Primary signet-ring cell carcinoma of the colon at early stage: a case report and a review of the literature. World J Gastroenterol (2006) 1.38
Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery. Gastric Cancer (2011) 1.36
Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol (2003) 1.35
Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol (2009) 1.34
Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology (2003) 1.34
PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res (2005) 1.34
Recurrence in early gastric cancer with lymph node metastasis. Gastric Cancer (2009) 1.33
Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun (2008) 1.33
Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol (2007) 1.33
Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group Study JCOG 0404. Ann Surg (2014) 1.32
Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res (2004) 1.32
Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol (2008) 1.31
In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells (2005) 1.31
Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg (2014) 1.31
Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res (2004) 1.29